Abstract:
Objective To ensure the median effective dose (ED50) of intravenous lidocaine in advance in preventing propofol medium-/long-chain triglyceride emulsion injection pain.
Methods Patients for elective surgery undergoing general anesthesia American Society of Anesthesiologists (ASA) grade Ⅰ or Ⅱwere selected. Lidocaine was administered intravenously prior to propofol medium-/long-chain triglyceride at an initial dose of 0.5 mg/kg lean body mass (LBW). The dose of lidocaine was adjusted by Dixon sequential method according to injection pain. Injection pain and adverse reactions were recorded. The ED50 and 95%CI of lidocaine were calculated. Patients'memory of injection pain in postanesthesia care unit (PACU) was recorded and Visual Analogue Scale (VAS) was evaluated.
Results A total of 30 patients completed the trial, including 19 patients with effective pain relief and 11 patients with ineffective pain relief. The ED50 of lidocaine in advance to prevent propofol medium-/long-chain triglyceride emulsion injection pain was 0.306 mg/kg (95%CI, 0.262 to 0.357 mg/kg) LBW. In PACU, 90.9% of the pain-experienced patients had memory of injection pain, and VAS score was (2.8±1.8).
Conclusion Prophylactic intravenous lidocaine for 0.306 mg/kg LBW could effectively prevent propofol medium-/long-chain triglyceride emulsion injection pain in 50.0% of patients for elective surgery undergoing general anesthesia without adverse reactions occurred.